Category - Developments

Developments

Altamira, Wellesta in LOU to distribute Bentrio in 6 key Asian markets

Altamira Therapeutics (NASDAQ:CYTO) signed a letter of understanding (LOU) with Singapore’s Wellesta Holdings for the marketing and distribution of Bentrio, its nasal spray for protection against airborne viruses and...

October 25, 2021

Developments

111, Inc., Chugai Pharma China in strategic partnership to accelerate chronic disease management

111, Inc. (NASDAQ:YI) entered into a strategic cooperation agreement with Chugai Pharma China. The agreement would allow the two companies to build a “Healthy China” by establishing a “SMART Healthcare...

October 25, 2021

Developments

Titan Pharma receives funding from Gates Foundation for combination HIV therapeutic and contraceptive implant for women in developing countries

Titan Pharmaceuticals (NASDAQ:TTNP) has received funding from the Bill & Melinda Gates Foundation to support its ability to deliver a human immunodeficiency virus (HIV) preventative therapeutic and a contraceptive...

October 25, 2021

Developments

PharmaJet, WHO, Gates Foundation in Somalia polio vaccination campaign

Closely held PharmaJet’s Tropis intradermal needle-free injection system is being used in a campaign in Somalia, delivering inactivated polio vaccine to more than 110,000 children. The purpose of the campaign, funded in...

October 21, 2021

Developments

HashCo launches premium craft-style hash products

The Hash Corporation (CSE:REZN) launched its suite of specialty hash products – Gold Seal Hash and Cold Tumbled Resin – to licensed retailers via the Ontario Cannabis Store. Both products are manufactured by a...

October 21, 2021

Developments

Sio Gene presents positive interim Phase 1/2 data in GM1 gangliosidosis

Sio Gene Therapies (NASDAQ:SIOX) presented positive interim data from its ongoing Phase 1/2 study of AXO-AAV-GM1, its adeno-associated viral vector 9-based gene therapy candidate for the treatment of GM1 gangliosidosis...

October 21, 2021

Developments

FDA clears Cognetivity’s cognitive assessment test

The FDA approved Cognetivity Neurosciences’ (CSE:CGN; OTCQB:CGNSF; FWB:1UB) 510(k) submission of its Integrated Cognitive Assessment (ICA) as a Class 2 exempt medical device, clearing the way for a commercial rollout...

October 20, 2021

Developments

NeoTX enrolls first patient in Phase 2a NAP trial in NSCLC

Closely held NeoTX Therapeutics of Israel enrolled the first patient in its Phase 2a clinical trial of naptumomab estafenatox (NAP), its lead tumor targeted superantigen candidate, in combination with docetaxel in...

October 20, 2021

Developments

111, Inc. executive chairman Dr. YU Gang receives 2021 China Artificial Intelligence Award

Dr. YU Gang, co-founder and executive chairman of 111, Inc. (NASDAQ:YI), received the 2021 China AI Golden Goose Award for outstanding achievements. In accepting the award at the 2021 China Artificial Intelligence...

October 19, 2021

Developments

Entasis posts positive topline Phase 3 results with SUR-DUR

Entasis Therapeutics (NASDAQ:ETTX) announced positive topline results from its ATTACK global Phase 3 trial evaluating the safety and efficacy of SUL-DUR (sulbactam-durlobactam) versus colistin in patients with...

October 19, 2021

Category - Developments

Subscribe